Tubal patency following surgical and clinical treatment of ectopic pregnancy.
OBJECTIVE
As there is little information about fertility outcomes among women following clinical treatment (methotrexate and expectant management) and surgery (salpingectomy) consequent to ectopic pregnancy, we evaluate the results from hysterosalpingography subsequent to treatment. The objective was to evaluate contralateral tubal patency using hysterosalpingography following surgery and clinical treatment of tubal pregnancy.


METHODS
This was a prospective study at the Department of Obstetrics of Universidade Federal de São Paulo, a tertiary center.


METHODS
Among 115 patients who underwent hysterosalpingography following surgery and clinical treatment of tubal pregnancy between April 1994 and February 2002, 30 were treated with a single intramuscular dose of methotrexate (50 mg/m(2)), 50 were followed up expectantly and 35 underwent salpingectomy.


RESULTS
The patency of the ipsilateral tube was 84% after methotrexate treatment and 78% after expectant management. In addition, contralateral tubal patency was 97% after methotrexate treatment, 92% after expectant management and 83% after salpingectomy. There were no statistically significant differences between the clinical treatment and surgery groups.


CONCLUSIONS
The findings from this study suggest similar contralateral tubal patency rates following salpingectomy, methotrexate treatment and expectant management.
Elito Junior
Julio
J
Department of Obstetrics, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Maria Carolina 68, Jardim Paulistano, São Paulo (SP), CEP 01445-000, Brazil. elitojr@hotmail.com
Han
Kyung Koo
KK
Camano
Luiz
L
D000020:Abortifacient Agents, Nonsteroidal / Q000627:therapeutic use; D016009:Chi-Square Distribution; D005184:Fallopian Tube Diseases / Q000000981:diagnostic imaging*; D005186:Fallopian Tube Patency Tests; D005187:Fallopian Tubes / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007047:Hysterosalpingography; D007247:Infertility, Female / Q000175:diagnosis; D008727:Methotrexate / Q000627:therapeutic use; D011184:Postoperative Period; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011446:Prospective Studies; D012489:Salpingostomy; D013997:Time Factors
D000020:Abortifacient Agents, Nonsteroidal; D008727:Methotrexate